Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours - Université de Lille
Article Dans Une Revue Current Pharmaceutical Design Année : 2021

Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours

Résumé

Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol. There is a need to look at novel approaches to target glioblastoma.Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant to glioblastomaMethods: Information on glioblastoma, cancer microenvironment, cancer therapeutics and how to improve the scenario was obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science Direct, Springer, Wiley online library and some data was harvested from regulatory and compliance databases such as clinicaltrials.gov, FDA database, WHO Globocan.Results and Conclusions: Currently, only a limited number of therapies are approved for GBM, and no standard of care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease and its underlying mechanisms.
Fichier principal
Vignette du fichier
P21.29 Bouckaert_Manuscript_Revised.pdf (592.81 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03381961 , version 1 (18-10-2021)
hal-03381961 , version 2 (07-03-2022)
hal-03381961 , version 3 (21-10-2022)

Identifiants

Citer

Shubham Semwal, Rabah Boukherroub, Savvas Savvides, Julie Bouckaert. Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours. Current Pharmaceutical Design, 2021, Current Pharmaceutical Design, 27 (45), pp.4515-4529. ⟨10.2174/1381612827666210728103524⟩. ⟨hal-03381961v3⟩
136 Consultations
106 Téléchargements

Altmetric

Partager

More